Archive

April 23, 2025

Browsing

Jammu and Kashmir Bank shares declined sharply on Wednesday, falling nearly 9% in early trade after a terror attack in the popular tourist destination of Pahalgam in the north Indian region of Jammu & Kashmir left at least 26 civilians dead.

The incident, which occurred on Tuesday afternoon at Baisaran, a scenic meadow often called “mini Switzerland,” has raised fears of heightened instability in the region and triggered a negative reaction from investors.

The stock dropped as much as 8.6% on the BSE, hitting an intraday low of ₹103.41 per share.

On the National Stock Exchange (NSE) and BSE combined, nearly 16.1 million shares were traded by 10:30 AM, significantly above the two-week average volume.

On the BSE alone, around 0.70 million shares changed hands, well above the recent average of 0.52 million shares.

At 1:10 pm IST, the stock was down by 8.05%.

According to Deepak Jasani, a stock market veteran quoted in Business Standard, the stock experienced a knee-jerk reaction on the downside.

“The evolving situation in the region will drive sentiment in the stock over the coming days. The stock may recover with some gap if the situation does not deteriorate further,” he said.

One of the deadliest attacks on civilians; TRF takes responsibility

The attack occurred around 3 PM on Tuesday in Baisaran, located about six kilometres from Pahalgam in Jammu and Kashmir.

The meadow is a well-known tourist attraction, drawing visitors from across India and abroad during spring and summer months.

The Resistance Front (TRF), a proxy of the banned Pakistan-based Lashkar-e-Taiba group, claimed responsibility for the attack.

In a public statement, Jammu and Kashmir Chief Minister Omar Abdullah said the assault was “much larger than anything we’ve seen directed at civilians in recent years,” hinting at the potential implications for both local security and regional geopolitics.

The incident has drawn international condemnation. US President Donald Trump, Russian President Vladimir Putin, and British Prime Minister Keir Starmer all issued statements denouncing the attack and expressing solidarity with India.

Retaliation by India could lead to short-term market volatility: analysts

Despite the tragic incident, broader Indian markets continued their upward momentum, with benchmark indices extending their rally for a seventh consecutive session on Wednesday.

Analysts believe this reflects investor confidence in the resilience of the Indian economy, although geopolitical concerns remain in focus.

Vinit Bolinjkar, Head of Research at Ventura Securities, said any retaliation by India could lead to short-term market volatility.

“Unless India undertakes strong military action against Pakistan, any market reaction may be limited. We’ve already seen the markets absorb extreme events like the Russia-Ukraine war and the US-China tariff standoff under President Trump,” he said.

Kranthi Bathini, Director of Equity Strategy at WealthMills Securities, echoed this view.

He stated that investors would be closely watching the government’s next steps, whether through diplomatic measures, targeted operations, or a wider military response.

“Today’s macroeconomic backdrop is very different from what it was during the 1999 Kargil War. India’s GDP has grown more than tenfold in just over two decades,” Bathini added, suggesting that the country is now better positioned to absorb such geopolitical shocks.

Veteran analyst Ajay Bagga noted on X (formerly Twitter) that while markets may stay cautious in the near term, any declines in the wake of potential Indian retaliation would likely be short-lived, as seen in past instances.

The post Pahalgam terror attack: J&K Bank shares fall; analysts warn of short-term volatility if India retaliates appeared first on Invezz

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

According to Grandview Research, the global biotech market is expected to grow at a compound annual growth rate of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

Read on to learn what’s been driving these Canadian biotech firms.

1. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 2,681.82 percent
Market cap: C$322.61 million
Share price: C$45.90

Bright Minds Biosciences is focused on developing novel treatments for neuropsychiatric disorders and pain.

Its portfolio consists of serotonin agonists designed to target neurocircuit abnormalities that make disorders like epilepsy, post-traumatic stress disorder and depression difficult to treat. The company’s drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing their side effects, thereby creating superior drugs to first-generation compounds such as psilocybin.

In October 2024, the company’s share price surged nearly 1,500 percent in a single session after global pharmaceutical company H. Lundbeck announced its intention to acquire Longboard Pharmaceuticals. Both Longboard and Bright Minds have agonists targeting the 5-HT2C receptorin their pipelines.

Bright Minds’ 5-HT2C agonist candidate, BMB-101, will target classic absence epilepsy and developmental epileptic encephalopathy. The company is currently evaluating Phase II trials in collaboration with Firefly Neuroscience (NASDAQ:AIFF).

In March of this year, Bright Minds added five world-renowned leaders in epilepsy research to its scientific advisory board.

2. ME Therapeutics Holdings (CSE:METX)

Year-on-year gain: 145.9 percent
Market cap: C$235.71 million
Share price: C$9.00

ME Therapeutics is a biotechnology company focused on developing cancer-fighting drug candidates that can increase the efficacy of current immuno-oncology drugs by targeting suppressive myeloid cells, which have been found to hinder the effectiveness of existing immuno-oncology treatments. Immuno-oncology is a relatively new area of cancer drug research and has shown promising results when used to treat cancer with low survival rates.

In December 2023, the company shared research done in collaboration with Dr. Kenneth Harder at the University of British Columbia. The work suggests that ME Therapeutics’ antibody, h1B11-12, successfully blocks a protein that fuels breast and colon cancer growth (G-CSF). Trial planning efforts are ongoing, and the company expects development of a cell line for future production of the drug to be finished in the latter half of 2025.

In addition, the company is part of an ongoing collaborative effort to develop therapeutic MRNA delivery methods to myeloid cells with NanoVation Therapeutics, a privately owned biotech company that develops customized nucleic acid and lipid nanoparticle technologies to empower genetic medicine.

The collaboration has already resulted in two new MRNA formulations, for which testing began on October 4, and has demonstrated encouraging anti-cancer activity in a preclinical model of colorectal cancer.

On March 3, ME Therapeutics shared that it is exploring a listing on the Nasdaq or the New York Stock Exchange.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 80 percent
Market cap: C$13.36 million
Share price: C$0.09

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, an approach that uses a patient’s own cells to theoretically enhance safety and efficacy. Its main product, ACP-01, is a cell therapy derived from a patient’s blood to promote tissue repair and regeneration in areas affected by disease.

The company announced its first sales orders for ACP-01 on January 29 and has been working to expand internationally and attract new investment.

Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia. As of writing, efforts to fully enroll the trial to its target size are underway.

4. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 17.07 percent
Market cap: C$173.51 million
Share price: C$5.28

Eupraxia Pharmaceuticals focuses on developing locally delivered therapeutics for patients with unmet medical needs. Its primary focus has been orthopedics and oncology. Eupraxia acquired EpiPharma Therapeutics in late 2023, absorbing the company’s lead candidate EP-104GI.

In February, the company released positive data from the sixth cohort of its Phase 1b/2a trial for EP-104GI in eosinophilic esophagitis. It plans to release additional data periodically, with 12 week data for the trial’s seventh cohort expected in late Q2 2025.

5. Microbix Biosystems (TSX:MBX)

Year-on-year gain: 4.48 percent
Market cap: C$48.17 million
Share price: C$0.35

Microbix Biosystems manufactures antigens and quality control products used in the development of diagnostic tests. They also develop products to ensure test accuracy.

In January, Microbix partnered with the American Proficiency Institute to launch a pilot program to validate the accuracy of molecular assays in testing the H5N1 strain of the influenza A virus.

In March, the company joined the EPICC HPV Elimination Partnership to support test accuracy by supplying materials to support the accuracy of HPV testing efforts. These strategic collaborations highlight the company’s commitment to ensuring reliable and accurate diagnostic testing worldwide.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

Chipotle Mexican Grill will open its first location in Mexico early next year as the latest stage in its international expansion.

The company announced Monday that it has signed a development agreement with Alsea, which operates Latin American and European locations of Starbucks, Domino’s Pizza and Burger King, among other chains.

After the initial restaurant opens in 2026, Chipotle plans to explore “additional expansion markets in the region,” which could mean broader Latin American development.

The deal to expand in Mexico comes as President Donald Trump wages a trade war with the country, straining the relationship between the two neighbors. Avocados from Mexico were originally subject to a 25% tariff until he paused new duties on goods compliant with the United States-Mexico-Canada Agreement. While Chipotle has diversified its avocado sourcing in recent years, it still imports about half of its avocados from Mexico.

In recent years, Chipotle has been trying to expand internationally, after decades focusing almost entirely on its U.S. business. The company operates 58 locations in Canada, 20 in the United Kingdom, six in France and two in Germany. Chipotle also currently has three restaurants in Kuwait and two in the United Arab Emirates through a deal with Alshaya Group.

Chipotle is betting that Mexico’s familiarity with its ingredients and appreciation for fresh food will win over consumers, according to a statement from Nate Lawton, Chipotle’s chief business development officer.

But U.S. interpretations of Mexican food don’t always resonate in the market; Yum Brands’ Taco Bell has twice attempted to expand into Mexico, but both efforts failed quickly.

This post appeared first on NBC NEWS

Rep. Dan Meuser, a Pennsylvania Republican, is supporting the White House’s proposed tax hike for people making more than $1 million. 

‘I believe we must help the President deliver on his promise of a tax and regulatory plan that supports pro-American economic and manufacturing growth, and delivers for the vast majority of Americans – while creating savings and promoting fiscal responsibility. Any adjustments in taxes to accomplish these goals should be considered,’ Meuser told Fox News Digital in a statement on Tuesday. 

Last week, White House aides began quietly floating a proposal to House Republicans that would raise the tax rate to 40% for Americans making more than $1 million, sources told Fox News Digital about the preliminary discussions. The plan would shore up income to fund President Donald Trump’s ambitious campaign promises to eliminate taxes on overtime, tips and Social Security.

On Thursday, Meuser said on ‘Mornings with Maria’ that he suggested a less than 2% tax hike for the ‘wealthy, high-end income’ tax bracket months ago. He noted that Trump’s 2017 Tax Cuts and Jobs Act lowered the top tax rate from 39.6% to 37%, so raising it to 38.6% would still keep it below the pre-TCJA level by nearly one percentage point.

‘We’re fighting for small business. We’re fighting for all of America and for the job creators that might be in those categories. So, if you were to bring it up by 1 point, it brings $15 billion in revenues, right? Without any elasticity, which could take place. So, if it did come up to 39[%], it’s almost $25 billion,’ Meuser said, touting the billions in revenue that a small tax hike could reap for the economy. 

The Pennsylvania Republican, who joined Trump on the 2024 campaign trail and is considered a potential candidate to challenge Gov. Josh Shapiro in 2026, stressed Trump’s all-of-the-above tax approach.

‘The president is determined not to have a standard – and this is my view, from what I’ve based upon him, I’m not putting in words in his mouth – a standard Republican-style budget. What he wants to see is something that is in the interest of all America, middle-income America, small businesses, and by the way, we would be talking about an exemption for pass-through small businesses so they would not be paying at the higher rate, as they do now, at their income level rate,’ Meuser said. 

While Meuser has indicated his warmth to the idea of tax hikes for the ultra-wealthy, other conservatives have remained steadfast in their rejection of any tax increases. 

Sen. Josh Hawley, R-Mo., told Fox News Digital last week that tax cuts are ‘what Republicans are good at’ as he urged his fellow Republicans to protect tax cuts for working-class Americans who fuel Trump’s base. More Republicans, including Sen. Mike Rounds of South Dakota and Rep. Tom Tiffany of Wisconsin are pushing to make Trump’s 2017 tax cuts permanent, which is considered a Republican priority during budget negotiations. 

Former Vice President Mike Pence, who refers to the 2017 tax cuts as the ‘Trump-Pence tax cuts,’ last week urged House Republicans to stand firm against raising taxes on the country’s top earners and make the 2017 tax cuts permanent. 

Advancing American Freedom, Pence’s conservative policy advocacy group, sent a letter to congressional Republicans, including House Ways and Means Committee Chair Rep. Jason Smith, R-Mo., and Senate Finance Committee Chair Sen. Mike Crapo, R-Idaho, last week, urging Congress to ‘stand firm against tax hikes.’

Fox News Digital’s Elizabeth Elkind contributed to this report.

This post appeared first on FOX NEWS